Neurodegenerative Disease News and Research

RSS

CPAP Therapy increases gray-matter volume in obstructive sleep apnea patients

Obstructive sleep apnea patients had reductions of grey-matter volume at baseline but showed significant grey-matter volume increase after three months of CPAP therapy, according to a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

Q Therapeutics, Inc. announced today that Piotr Walczak, M.D., of Johns Hopkins University has received notification of a $1,000,000 grant to be awarded by the Maryland Stem Cell Research Fund (MSCRF) which will enable further study of Q's human neural glial cell product Q-Cells® in preclinical models of demyelinating disease.

2 Jun 2010

New book to prevent Age-Related Macular Degeneration

A new prevention tool is now available, in both French and English, at local bookstores and pharmacies. Dr. Jean-Daniel Arbour and Dr. Pierre Labelle of the Universit- de Montr-al Department of Ophthalmology, along with two colleagues from France, have authored a new book to prevent vision loss, AMD: Age-Related Macular Degeneration (Annika Parance Publisher; 121 pages). Written to educate readers about the importance of vision health, the book provides clear explanations on the causes, consequences and treatments of AMD.

26 May 2010

Highlights from June 2010 issue of American Journal of Pathology

Dr. Kanneboyina Nagaraju and colleagues at the Children's National Medical Center, Washington, DC demonstrate that affected muscle may directly contribute to inflammation in muscular dystrophy. Their report can be found in the June 2010 issue of The American Journal of Pathology.

26 May 2010

Increasing levels of GGA3 protein prevent accumulation of enzyme linked to Alzheimer's disease

Researchers at Tufts University School of Medicine have zeroed in on a protein that may play a role in the progression of Alzheimer's disease. The team found that increasing levels of the protein (called GGA3) prevented the accumulation of an enzyme linked to Alzheimer's. The strategy may lead to new treatments for the neurodegenerative disease.

26 May 2010

ADDF provides $248,000 grant to ALSP to allow its lead drug candidate towards clinical trials

The Alzheimer's Drug Discovery Foundation announced today that it is providing a grant of $248,000 to American Life Science Pharmaceuticals, Inc. to allow for manufacture of its lead drug candidate to be used in preclinical toxicology testing in preparation for entering Phase I clinical trials early in 2011.

25 May 2010

Young Faces of ALS campaign to raise awareness on ALS

The ALS Therapy Development Institute announced today that it is supporting a new awareness campaign driven by several ALS patients diagnosed with the progressive neurodegenerative disease commonly known as Lou Gehrig's disease before the age of 30. This campaign, called "Young Faces of ALS," is designed and led by a group of seven young men and women and will consist of a group effort to visit each of the 30 Major League Baseball parks during the 2010 baseball season.

21 May 2010

European researchers define research priorities in biogerontology

The quality of the medical care for geriatric patients is a major investment for society and must imperatively be a research priority in Europe. This is why 50 European researchers, met on May 17 - 19 in Brussels, to define the research priorities in the field of biogerontology for the next 10 to 15 years.

21 May 2010

Study examines impact of APOE ε4 on cognitive function, brain anatomy in AD patients

In the most comprehensive study to date, neurologists have clearly identified significant differences in the ways that Alzheimer's disease affects patients with and without the apolipoprotein E ε4 gene, a known genetic risk factor for the neurodegenerative disease, using a combination of cognitive and neuroanatomic measures. The study found that this gene influences the way the disease manifests, even at its mildest clinical stages.

19 May 2010

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.

13 May 2010

Neurimmune Therapeutics honored with ZKB TECHNOPARK Pioneer Award

The ZKB TECHNOPARK® Pioneer Award, which has been sponsored by the Zürcher Kantonalbank since 2000, was presented for the 20th time at TECHNOPARK® Zurich. The award is given for technological innovations which - thanks to pioneering entrepreneurial achievements - are about to be launched on the market. This year's award winner is Neurimmune Therapeutics AG, represented by Dr. Jan Grimm, Professor Christoph Hock, Professor Roger Nitsch and Dr. Michael Salzmann.

12 May 2010

Researchers discover link between sporadic and familial forms of ALS

Researchers from Northwestern University Feinberg School of Medicine have discovered a link between sporadic and familial forms of amyotrophic lateral sclerosis, a neurodegenerative disease also known as Lou Gehrig's disease.

6 May 2010

Principals of StemTroniX, Power3 Medical Products file patent application

StemTroniX, Inc., a Texas corporation, and Power3 Medical Products, Inc. announced today that a joint provisional patent application entitled, "Stem Cell Protein Biomarkers and Their Use in Monitoring Stem Cells and Their Products for Stem Cell Therapy" has been filed by the principals of StemTroniX and Power3 with the United States Patent and Trademark Office.

5 May 2010

StemCells first-quarter total revenue up 307%

StemCells, Inc., a leading stem cell technology company with the dual focus of novel therapeutics and innovative research products, today reported financial results for the first quarter ended March 31, 2010 and recent business highlights.

5 May 2010

UCSF transgenic mouse model first to display earliest signs of Parkinson's disease

UCSF researchers have created the first transgenic mouse to display the earliest signs of Parkinson's disease using the genetic mutation that is known to accompany human forms of the disease.

4 May 2010

CSTE receives $1M gift from NFL to research long-term effects of repetitive brain trauma in football players

The National Football League (NFL) will give a $1 million unrestricted gift to the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine to support the Center's research.

21 Apr 2010

Researchers receive honorary Doctor of Medicine degrees

Two genetics researchers from the Johns Hopkins University School of Medicine have been awarded prestigious honorary Doctor of Medicine degrees by European scientific institutions.

17 Apr 2010

EU Joint Programming initiative to tackle neurodegenerative diseases

Leading researchers from across Europe will gather today in Stockholm to develop a European-wide research strategy to tackle neurodegenerative diseases such as Alzheimer's and Parkinson's Disease.

15 Apr 2010

Defective protein responsible for SCA5 disease cuts synaptic terminals and snarls traffic inside neurons

The neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve cells in two ways. University of Minnesota researchers now report that the defective protein responsible for the disease cuts the number of synaptic terminals and snarls traffic inside neurons.

7 Apr 2010

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

In an article published in Nature Genetics today, scientists at the ALS Therapy Development Institute describe how they have linked an unbiased gene expression profiling effort to the identification and successful preclinical testing of a potential novel therapeutic for amyotrophic lateral sclerosis.

29 Mar 2010

Neurodegenerative Disease News and Research

CPAP Therapy increases gray-matter volume in obstructive sleep apnea patients

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

New book to prevent Age-Related Macular Degeneration

Highlights from June 2010 issue of American Journal of Pathology

Increasing levels of GGA3 protein prevent accumulation of enzyme linked to Alzheimer's disease

ADDF provides $248,000 grant to ALSP to allow its lead drug candidate towards clinical trials

Young Faces of ALS campaign to raise awareness on ALS

European researchers define research priorities in biogerontology

Study examines impact of APOE ε4 on cognitive function, brain anatomy in AD patients

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Neurimmune Therapeutics honored with ZKB TECHNOPARK Pioneer Award

Researchers discover link between sporadic and familial forms of ALS

Principals of StemTroniX, Power3 Medical Products file patent application

StemCells first-quarter total revenue up 307%

UCSF transgenic mouse model first to display earliest signs of Parkinson's disease

CSTE receives $1M gift from NFL to research long-term effects of repetitive brain trauma in football players

Researchers receive honorary Doctor of Medicine degrees

EU Joint Programming initiative to tackle neurodegenerative diseases

Defective protein responsible for SCA5 disease cuts synaptic terminals and snarls traffic inside neurons

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

Aneuro: A Year of Neuroscience in Review eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News